Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 1:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gynecological Malignancies Clear all
Terminated Phase 1Phase 2 Interventional Results available

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

NCT04493619
View directory record Official record
Conditions
Gynecologic Neoplasms, Epithelial Ovarian Cancer
Interventions
PLX2853, Carboplatin
Drug
Lead sponsor
Opna Bio LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 5, 2026, 1:17 AM EDT
Terminated Phase 1 Interventional Results available

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

NCT02661815
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
Paclitaxel, Ricolinostat, Bevacizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 5, 2026, 1:17 AM EDT
Withdrawn Not applicable Interventional

Improving Insulin Resistance in Gynecological Cancer Patients

NCT04139694
View directory record Official record
Conditions
Insulin Resistance
Interventions
Food plan with cinnamon supplementation, Food plan without cinnamon supplementation
Dietary Supplement · Behavioral
Lead sponsor
Woman's
Other
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 5, 2026, 1:17 AM EDT
Active, not recruiting Not applicable Interventional

Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

NCT07120945
View directory record Official record
Conditions
Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis, Uterine Prolapse, Precancerous/Nonmalignant Condition, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
Robotic Assisted-Surgery (RAS) Hysterectomy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
22 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Jacksonville, Florida • Tampa, Florida • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 5, 2026, 1:17 AM EDT
Not listed No phase listed Observational

Questionnaire Study for Gynecological Cancer Survivors

NCT00391664
View directory record Official record
Conditions
Endometrial Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Genital Neoplasms, Female
Interventions
Psychosocial
Behavioral
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
20 Years to 75 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2008 · Synced Oct 5, 2026, 1:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment

NCT05562778
View directory record Official record
Conditions
Gynecologic Cancer, Hereditary Cancer Syndrome
Interventions
Chatbot
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
4
States / cities
Brooklyn, New York • New York, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

NCT01432015
View directory record Official record
Conditions
Ovarian Cancer, Uterine Cancer
Interventions
fosaprepitant, aprepitant, Oral Placebo, IV placebo
Drug · Other
Lead sponsor
Gynecologic Oncology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 5, 2026, 1:17 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

NCT05032040
View directory record Official record
Conditions
Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
vudalimab
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Prescott, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 5, 2026, 1:17 AM EDT
Completed No phase listed Observational

Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers

NCT02003430
View directory record Official record
Conditions
Non-ovarian Gynecological Cancers
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 5, 2026, 1:17 AM EDT
Recruiting Phase 2 Interventional

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

NCT05979610
View directory record Official record
Conditions
Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
Interventions
Reiki therapy
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 5, 2026, 1:17 AM EDT
Not yet recruiting Not applicable Interventional

Improving Sexual Health in Gynecological Cancer Patients

NCT07144566
View directory record Official record
Conditions
Gynaecologic Cancer
Interventions
Nurse Led Sexual Health Clinical Program Intervention
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies

NCT04258631
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
Hydromorphone, Laparotomy, Liposomal Bupivacaine, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

Accelerating Gastrointestinal Recovery

NCT01704651
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
Jamie N. Bakkum-Gamez
Other
Eligibility
18 Years and older · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 5, 2026, 1:17 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access of Vigil in Solid Tumors

NCT03842865
View directory record Official record
Conditions
Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Vigil
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery

NCT01867606
View directory record Official record
Conditions
Female Reproductive Cancer
Interventions
serum-derived bovine immunoglobulin protein isolate, placebo, laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Phase 3 Interventional Results available

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

NCT02855944
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Chemotherapy, Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Denver, Colorado • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Phase 2 Interventional Results available

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

NCT00545792
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer, Carcinoma of the Vulva
Interventions
Avastin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Not applicable Interventional

Enhanced Recovery After Surgery Gynecology Oncology

NCT02864277
View directory record Official record
Conditions
Malignant Female Reproductive System Neoplasm
Interventions
No Intervention Conventional Strategy, ERAS
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 5, 2026, 1:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

NCT04717349
View directory record Official record
Conditions
Disorders of Sex Development (DSD), Pediatric and Adolescent Cancers of the Genital Tract, Reproductive Endocrine Conditions in Puberty, Structural Gynecologic Conditions Including Vulvar and Vaginal Conditions
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
1 Day to 100 Years
Enrollment
11,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2039
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 5, 2026, 1:17 AM EDT
Completed Not applicable Interventional

Post-Operative Gynecological Oncology App Study

NCT02932098
View directory record Official record
Conditions
Genital Neoplasm, Female
Interventions
Discharge instructions reminders, Prompts to report symptoms via the web-enabled app, Clinical Alerts
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Southaven, Mississippi • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 5, 2026, 1:17 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Lidocaine Infusion or Quadratus Lumborum Block and Intrathecal Morphine, Versus Intrathecal Morphine Alone

NCT03658109
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Lidocaine Bolus Infusion, QL block, Saline Bolus Infusion, Simulated QL block
Drug · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 69 Years · Female only
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 5, 2026, 1:17 AM EDT
Active, not recruiting Phase 1 Interventional

Study of INCB123667 in Subjects With Advanced Solid Tumors

NCT05238922
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB0123667, Palbociclib, Bevacizumab, Olaparib, Paclitaxel, Ribociclib, Fulvestrant
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 5, 2026, 1:17 AM EDT
Not listed No phase listed Observational

Tissue Bank of Biological Specimens From Patients With Gynecologic Disease

NCT00299481
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Leiomyoma
Interventions
Not listed
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years and older · Female only
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Detroit, Michigan • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2008 · Synced Oct 5, 2026, 1:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Use of Pycnogenol® to Alleviate Menopausal Symptoms Induced or Increased by Breast and Gynecological Cancer Treatments

NCT03704454
View directory record Official record
Conditions
Climacteric; Menorrhagia, Menopausal, Menopause
Interventions
50 mg PYC and then placebo, 100 mg PYC and then placebo, Placebo and then 50 mg PYC, Placebo and then 100 mg PYC
Dietary Supplement
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Gresham, Oregon • Portland, Oregon • Tualatin, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 5, 2026, 1:17 AM EDT